What is the purpose of this trial?
This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 110 adult patients are expected to be enrolled in the study.
Alexo Therapeutics Inc.
Dates: 07/21/2017 - 01/01/2019
Last Updated: 07/23/2017
Study HIC#: 2000020159